Submitted:
17 July 2023
Posted:
18 July 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Results
2.1. Participant characteristics
2.2. Circulating NFL and its association with body composition.
2.3. Relationship between circulating NFL and functional performance tests.
2.4. Relationship between circulating NFL and metabolomic markers
3. Discussion
4. Materials and Methods
4.1. Study subjects
4.2. Physical performance test
4.3. Measurements of Body Composition
4.4. NFL serum levels
4.5. Measurement of plasma metabolites
4.6. Statistical analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The hallmarks of aging. Cell 2013, 153, 1194-1217. [CrossRef]
- Carson, R.G. Get a grip: individual variations in grip strength are a marker of brain health. Neurobiol Aging 2018, 71, 189-222. [CrossRef]
- Jiang, R.; Westwater, M.L.; Noble, S.; Rosenblatt, M.; Dai, W.; Qi, S.; Sui, J.; Calhoun, V.D.; Scheinost, D. Associations between grip strength, brain structure, and mental health in > 40,000 participants from the UK Biobank. BMC Medicine 2022, 20, 286. [CrossRef]
- Peel, N.M.; Kuys, S.S.; Klein, K. Gait Speed as a Measure in Geriatric Assessment in Clinical Settings: A Systematic Review. The Journals of Gerontology: Series A 2012, 68, 39-46. [CrossRef]
- Studenski, S.; Perera, S.; Patel, K.; Rosano, C.; Faulkner, K.; Inzitari, M.; Brach, J.; Chandler, J.; Cawthon, P.; Connor, E.B., et al. Gait Speed and Survival in Older Adults. JAMA 2011, 305, 50-58. [CrossRef]
- Dillon, K.; Goodman, Z.T.; Kaur, S.S.; Levin, B.; McIntosh, R. Neutrophil-to-Lymphocyte Ratio Amplifies the Effects of Aging on Decrements in Grip Strength and its Functional Neural Underpinnings. The Journals of Gerontology: Series A 2023, 10.1093/gerona/glad048. [CrossRef]
- Marks, J.D.; Syrjanen, J.A.; Graff-Radford, J.; Petersen, R.C.; Machulda, M.M.; Campbell, M.R.; Algeciras-Schimnich, A.; Lowe, V.; Knopman, D.S.; Jack, C.R., Jr., et al. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimers Res Ther 2021, 13, 021-00944. [CrossRef]
- Shen, X.N.; Li, J.Q.; Wang, H.F.; Li, H.Q.; Huang, Y.Y.; Yang, Y.X.; Tan, L.; Dong, Q.; Yu, J.T. Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia. Alzheimers Dement 2020, 12. [CrossRef]
- Khalil, M.; Pirpamer, L.; Hofer, E.; Voortman, M.M.; Barro, C.; Leppert, D.; Benkert, P.; Ropele, S.; Enzinger, C.; Fazekas, F., et al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nature Communications 2020, 11, 812. [CrossRef]
- Gaetani, L.; Blennow, K.; Calabresi, P.; Filippo, M.D.; Parnetti, L.; Zetterberg, H. Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery & Psychiatry 2019, 90, 870-881. [CrossRef]
- Karoly, H.C.; Skrzynski, C.J.; Moe, E.; Bryan, A.D.; Hutchison, K.E. Investigating Associations Between Inflammatory Biomarkers, Gray Matter, Neurofilament Light and Cognitive Performance in Healthy Older Adults. Front Aging Neurosci 2021, 13. [CrossRef]
- Jakimovski, D.; Zivadinov, R.; Ramanthan, M.; Hagemeier, J.; Weinstock-Guttman, B.; Tomic, D.; Kropshofer, H.; Fuchs, T.A.; Barro, C.; Leppert, D., et al. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study. Mult Scler 2020, 26, 1670-1681. [CrossRef]
- Vacchiano, V.; Mastrangelo, A.; Zenesini, C.; Masullo, M.; Quadalti, C.; Avoni, P.; Polischi, B.; Cherici, A.; Capellari, S.; Salvi, F., et al. Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study. Front Aging Neurosci 2021, 13. [CrossRef]
- Wang, S.Y.; Chen, W.; Xu, W.; Li, J.Q.; Hou, X.H.; Ou, Y.N.; Yu, J.T.; Tan, L. Neurofilament Light Chain in Cerebrospinal Fluid and Blood as a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis. J Alzheimers Dis 2019, 72, 1353-13. [CrossRef]
- Loeffler, T.; Schilcher, I.; Flunkert, S.; Hutter-Paier, B. Neurofilament-Light Chain as Biomarker of Neurodegenerative and Rare Diseases With High Translational Value. Front Neurosci 2020, 14. [CrossRef]
- Ladang, A.; Kovacs, S.; Lengelé, L.; Locquet, M.; Reginster, J.Y.; Bruyère, O.; Cavalier, E. Neurofilament light chain concentration in an aging population. Aging Clin Exp Res 2022, 34, 331-339. [CrossRef]
- Meeker, K.L.; Butt, O.H.; Gordon, B.A.; Fagan, A.M.; Schindler, S.E.; Morris, J.C.; Benzinger, T.L.S.; Ances, B.M. Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage. Neurobiology of disease 2022, 166, 105662. [CrossRef]
- Barro, C.; Chitnis, T.; Weiner, H.L. Blood neurofilament light: a critical review of its application to neurologic disease. Ann Clin Transl Neurol 2020, 7, 2508-2523. [CrossRef]
- Koini, M.; Pirpamer, L.; Hofer, E.; Buchmann, A.; Pinter, D.; Ropele, S.; Enzinger, C.; Benkert, P.; Leppert, D.; Kuhle, J., et al. Factors influencing serum neurofilament light chain levels in normal aging. Aging 2021, 13, 25729-25738. [CrossRef]
- Aamodt, W.W.; Waligorska, T.; Shen, J.; Tropea, T.F.; Siderowf, A.; Weintraub, D.; Grossman, M.; Irwin, D.; Wolk, D.A.; Xie, S.X., et al. Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. Movement disorders : official journal of the Movement Disorder Society 2021, 36, 2945-2950. [CrossRef]
- Manouchehrinia, A.; Piehl, F.; Hillert, J.; Kuhle, J.; Alfredsson, L.; Olsson, T.; Kockum, I. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann Clin Transl Neurol 2020, 7, 139-143. [CrossRef]
- Bourgognon, J.M.; Steinert, J.R. The metabolome identity: basis for discovery of biomarkers in neurodegeneration. Neural Regen Res 2019, 14, 387-390. [CrossRef]
- Shao, Y.; Le, W. Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease. Molecular neurodegeneration 2019, 14, 3. [CrossRef]
- Tian, Q.; Shardell, M.D.; Kuo, P.L.; Tanaka, T.; Simonsick, E.M.; Moaddel, R.; Resnick, S.M.; Ferrucci, L. Plasma metabolomic signatures of dual decline in memory and gait in older adults. GeroScience 2023, 10.1007/s11357-023-00792-8. [CrossRef]
- Tian, Q.; Schrack, J.A.; Landman, B.A.; Resnick, S.M.; Ferrucci, L. Longitudinal associations of absolute versus relative moderate-to-vigorous physical activity with brain microstructural decline in aging. Neurobiol Aging 2022, 116, 25-31. [CrossRef]
- Estes, R.E.; Lin, B.; Khera, A.; Davis, M.Y. Lipid Metabolism Influence on Neurodegenerative Disease Progression: Is the Vehicle as Important as the Cargo? Frontiers in molecular neuroscience 2021, 14, 788695. [CrossRef]
- Socha, E.; Kośliński, P.; Koba, M.; Mądra-Gackowska, K.; Kędziora-Kornatowska, K.; Gackowski, M.; Daghir-Wojtkowiak, E. Amino Acid Levels as Potential Biomarker of Elderly Patients with Dementia. Brain Sci 2020, 10. [CrossRef]
- Lin, C.H.; Yang, H.T.; Chiu, C.C.; Lane, H.Y. Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging. Sci Rep 2017, 7, 017-13951. [CrossRef]
- Polis, B.; Samson, A.O. Role of the metabolism of branched-chain amino acids in the development of Alzheimer's disease and other metabolic disorders. Neural Regen Res 2020, 15, 1460-1470. [CrossRef]
- Moaddel, R.; Fabbri, E.; Khadeer, M.A.; Carlson, O.D.; Gonzalez-Freire, M.; Zhang, P.; Semba, R.D.; Ferrucci, L. Plasma Biomarkers of Poor Muscle Quality in Older Men and Women from the Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci 2016, 71, 1266-1272. [CrossRef]
- Gonzalez-Freire, M.; Moaddel, R.; Sun, K.; Fabbri, E.; Zhang, P.; Khadeer, M.; Salem, N., Jr.; Ferrucci, L.; Semba, R.D. Targeted Metabolomics Shows Low Plasma Lysophosphatidylcholine 18:2 Predicts Greater Decline of Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging. J Gerontol A Biol Sci Med Sci 2019, 74, 62-67. [CrossRef]
- Semba, R.D.; Zhang, P.; Adelnia, F.; Sun, K.; Gonzalez-Freire, M.; Salem, N., Jr.; Brennan, N.; Spencer, R.G.; Fishbein, K.; Khadeer, M., et al. Low plasma lysophosphatidylcholines are associated with impaired mitochondrial oxidative capacity in adults in the Baltimore Longitudinal Study of Aging. Aging Cell 2019, 18, e12915. [CrossRef]
- Vints, W.A.J.; Kušleikienė, S.; Sheoran, S.; Valatkevičienė, K.; Gleiznienė, R.; Himmelreich, U.; Pääsuke, M.; Česnaitienė, V.J.; Levin, O.; Verbunt, J., et al. Body fat and components of sarcopenia relate to inflammation, brain volume, and neurometabolism in older adults. Neurobiol Aging 2023, 127, 1-11. [CrossRef]
- Traylor, M.K.; Bauman, A.J.; Saiyasit, N.; Frizell, C.A.; Hill, B.D.; Nelson, A.R.; Keller, J.L. An examination of the relationship among plasma brain derived neurotropic factor, peripheral vascular function, and body composition with cognition in midlife African Americans/Black individuals. Front Aging Neurosci 2022, 14, 980561. [CrossRef]
- Mielke, M.M.; Syrjanen, J.A.; Blennow, K.; Zetterberg, H.; Skoog, I.; Vemuri, P.; Machulda, M.M.; Graff-Radford, J.; Knopman, D.S.; Jack, C.R., Jr., et al. Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin. Alzheimers Dement 2019, 15, 1437-1447. [CrossRef]
- Bridel, C.; van Wieringen, W.N.; Zetterberg, H.; Tijms, B.M.; Teunissen, C.E.; Alvarez-Cermeño, J.C.; Andreasson, U.; Axelsson, M.; Bäckström, D.C.; Bartos, A., et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol 2019, 76, 1035-1048. [CrossRef]
- Peterson, M.D.; Collins, S.; Meier, H.C.S.; Brahmsteadt, A.; Faul, J.D. Grip strength is inversely associated with DNA methylation age acceleration. Journal of Cachexia, Sarcopenia and Muscle 2023, 14, 108-115. [CrossRef]
- White, D.K.; Neogi, T.; Nevitt, M.C.; Peloquin, C.E.; Zhu, Y.; Boudreau, R.M.; Cauley, J.A.; Ferrucci, L.; Harris, T.B.; Satterfield, S.M., et al. Trajectories of gait speed predict mortality in well-functioning older adults: the Health, Aging and Body Composition study. J Gerontol A Biol Sci Med Sci 2013, 68, 456-464. [CrossRef]
- Pratt, J.; De Vito, G.; Segurado, R.; Pessanha, L.; Dolan, J.; Narici, M.; Boreham, C. Plasma neurofilament light levels associate with muscle mass and strength in middle-aged and older adults: findings from GenoFit. J Cachexia Sarcopenia Muscle 2022, 13, 1811-1820. [CrossRef]
- He, L.; de Souto Barreto, P.; Aggarwal, G.; Nguyen, A.D.; Morley, J.E.; Li, Y.; Bateman, R.J.; Vellas, B.; Vellas, B.; Guyonnet, S., et al. Plasma Aβ and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults. Alzheimer's Research & Therapy 2020, 12, 128. [CrossRef]
- D'Emanuele, S.; Maffiuletti, N.A.; Tarperi, C.; Rainoldi, A.; Schena, F.; Boccia, G. Rate of Force Development as an Indicator of Neuromuscular Fatigue: A Scoping Review. Frontiers in human neuroscience 2021, 15, 701916. [CrossRef]
- Kwon, I.; Kim, J.S.; Shin, C.H.; Park, Y.; Kim, J.H. Associations Between Skeletal Muscle Mass, Grip Strength, and Physical and Cognitive Functions in Elderly Women: Effect of Exercise with Resistive Theraband. Journal of exercise nutrition & biochemistry 2019, 23, 50-55. [CrossRef]
- Sawada, S.; Ozaki, H.; Natsume, T.; Deng, P.; Yoshihara, T.; Nakagata, T.; Osawa, T.; Ishihara, Y.; Kitada, T.; Kimura, K., et al. The 30-s chair stand test can be a useful tool for screening sarcopenia in elderly Japanese participants. BMC musculoskeletal disorders 2021, 22, 639. [CrossRef]
- Hermesdorf, M.; Leppert, D.; Maceski, A.; Benkert, P.; Wellmann, J.; Wiendl, H.; Kuhle, J.; Berger, K. Longitudinal analyses of serum neurofilament light and associations with obesity indices and bioelectrical impedance parameters. Sci Rep 2022, 12, 15863. [CrossRef]
- Xu, T.L.; Gong, N. Glycine and glycine receptor signaling in hippocampal neurons: diversity, function and regulation. Progress in neurobiology 2010, 91, 349-361. [CrossRef]
- Newcomer, J.W.; Farber, N.B.; Olney, J.W. NMDA receptor function, memory, and brain aging. Dialogues in clinical neuroscience 2000, 2, 219-232. [CrossRef]
- Zhou, Y.; Danbolt, N.C. Glutamate as a neurotransmitter in the healthy brain. Journal of neural transmission (Vienna, Austria : 1996) 2014, 121, 799-817. [CrossRef]




| Participants characteristics | ||||
|---|---|---|---|---|
| Total | Male | Female | p | |
| N | 40 | 20 | 20 | |
| Age (years) | 47.8 ± 2.79 | 48.9 ± 3.83 | 46.7± 4.15 | 0.565 |
| BMI (kg/m2) | 23.7 ± 0.54 | 24.8 ± 0.59 | 22.5 ± 0.83* | 0.026 |
| Comorbidities | ||||
| Hypertension | 3 (7.50 %) | 2 (10.0%) | 1 (5.00%) | 0.458 |
| Asthma | 3 (7.50 %) | 1 (5.00%) | 2 (10.0%) | 0.503 |
| Hypercholesterolemia | 5 (12.5 %) | 3 (15.0%) | 2 (10.0%) | 0.516 |
| Physical performance | ||||
| 4-m gait speed at usual pace (m/s) | 1.17 ± 0.03 | 1.16 ± 0.03 | 1.18 ± 0.03 | 0.632 |
| 4-m gait speed at fast pace (m/s) | 1.81 ± 0.04 | 1.89 ± 0.05 | 1.71 ± 0.05* | 0.022 |
| Grip Strength (kg) | 30.4 ± 1.76 | 39.4 ± 1.45 | 21.4 ± 1.42* | <0.001 |
| Chair test (s) | 9.39 ± 0.47 | 9.37 ± 0.74 | 9.4 ± 0.60 | 0.980 |
| NFL | ||||
| NFL (pg/mL) | 14.7 ± 1.13 | 14.0 ± 1.54 | 15.3 ± 1.69 | 0.561 |
| Body Composition | ||||
| Intracellular Water (L) | 23.9 ± 0.94 | 28.6 ± 1.01 | 19.3 ± 0.57* | <0.001 |
| Extracellular area (L) | 14.5 ± 0.54 | 17.3 ± 0.55 | 11.8 ±0.30 * | <0.001 |
| Body Fat Mass (Kg) | 15.9 ± 1.09 | 15.6 ± 1.41 | 16.2 ± 1.69 | 0.792 |
| Soft Lean Mass (Kg) | 49.4 ±1.91 | 58.9 ± 2.02 | 39.9 ± 1.13 * | <0.001 |
| Fat Free Mass (Kg) | 52.4 ± 2.01 | 62.5 ± 2.14 | 42.4 ± 1.19 * | <0.001 |
| Fat percentage (%) | 23.4 ± 1.39 | 19.8 ± 1.58 | 26.9 ± 2.04 * | <0.001 |
| Visceral fat area (cm2) | 74.9 ± 6.24 | 72.8 ± 7.69 | 77.1 ± 10.1 | 0.733 |
| Waist Hip Ratio | 0.90 ± 0.01 | 0.91 ± 0.02 | 0.88 ± 0.02 | 0.387 |
| SKM index | 7.20 ± 0.19 | 8.18 ± 0.19 | 6.23 ± 0.15 * | <0.001 |
| 50 kH body phase angle | 5.53± 0.13 | 5.88 ± 0.17 | 5.16 ±0.15 * | 0.003 |
| Total (N=40) | Males (N=20) | Females (N=20) | ||||
|---|---|---|---|---|---|---|
| R | p | r | p | r | p | |
| NFL vs Physical performance tests | ||||||
| Chair test (s) | 0.509 | 0.01* | 0.478 | 0.033* | 0.008 | 0.975 |
| Grip strength (kg) | -0.202 | 0.211 | -0.535 | 0.015* | 0.108 | 0.650 |
| 4-m gait speed at usual pace (m/s) | -0.223 | 0.167 | -0.460 | 0.041* | -0.047 | 0.843 |
| 4-m gait speed at fast pace (m/s) | -0.284 | 0.076 | -0.423 | 0.063 | 0.131 | 0.582 |
| NFL vs Body composition | ||||||
| Intracellular water | -0.168 | 0.300 | -0.384 | 0.095 | 0.169 | 0.477 |
| Extracellular water | -0.130 | 0.424 | -0.255 | 0.279 | 0.220 | 0.350 |
| Body fat mass | 0.284 | 0.075 | 0.482 | 0.031* | 0.006 | 0.980 |
| Soft Lean Mass | -0.152 | 0.349 | -0.320 | 0.168 | 0.168 | 0.478 |
| Fat Free Mass | -0.153 | 0.347 | -0.331 | 0.154 | 0.177 | 0.456 |
| Fat Percentage | 0.337 | 0.034* | 0.496 | 0.026* | -0.052 | 0.828 |
| Visceral Fat Area | 0.319 | 0.045* | 0.516 | 0.020* | 0.112 | 0.638 |
| Waist Hip Ratio | 0.155 | 0.339 | 0.354 | 0.126 | -0.048 | 0.840 |
| 50 kHz body phase angle | -0.406 | 0.009* | -0.603 | 0.005* | -0.182 | 0.442 |
| NFL vs Metabolomic markers | ||||||
| ASP | 0.371 | 0.018* | 0.320 | 0.169 | 0.446 | 0.049* |
| GLU | 0.181 | 0.264 | 0.445 | 0.050* | 0.000 | 1.000 |
| GLY | -0.215 | 0.183 | -0.608 | 0.004* | 0.062 | 0.796 |
| SER | -0.249 | 0.122 | -0.443 | 0.050* | -0.055 | 0.818 |
| Putrescine | 0.428 | 0.006* | 0.419 | 0.066 | 0.463 | 0.040* |
| TAU | 0.317 | 0.046* | 0.293 | 0.209 | 0.335 | 0.148 |
| KYN | 0.319 | 0.045* | 0.253 | 0.283 | 0.386 | 0.092 |
| LysoPC_aa_C17:0 | 0.204 | 0.207 | -0.084 | 0.726 | 0.492 | 0.028* |
| LysoPC_aa_C18:2 | -0.111 | 0.495 | -0.458 | 0.042* | 0.347 | 0.133 |
| PC_aa_C36:5 | 0.395 | 0.013* | 0.564 | 0.010* | 0.214 | 0.379 |
| PC_aa_C36:6 | 0.309 | 0.056 | 0.460 | 0.041* | 0.096 | 0.697 |
| PC_aa_C38:6 | 0.191 | 0.245 | 0.513 | 0.021* | -0.183 | 0.454 |
| PC_aa_C42:5 | 0.194 | 0.237 | 0.462 | 0.040* | 0.015 | 0.952 |
| PC_ae_C38:0 | 0.226 | 0.166 | 0.477 | 0.034* | -0.016 | 0.949 |
| PC.aa.C40.3 | 0.322 | 0.046* | 0.299 | 0.200 | 0.282 | 0.241 |
| PC_ae_C42:3 | 0.349 | 0.030* | 0.110 | 0.645 | 0.579 | 0.009* |
| PC_ae_C44:4 | 0.457 | 0.003* | 0.490 | 0.028* | 0.447 | 0.055 |
| Acetylcarnitine | 0.325 | 0.041* | 0.335 | 0.148 | 0.344 | 0.137 |
| OH-Sphingomyelin C22.2 | 0.318 | 0.045* | 0.325 | 0.128 | 0.227 | 0.336 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).